Jakub Kosma Rokicki

Dr. Jakub Kosma Rokicki

Department of Medical Informatics and Telemedicine, Medical Univerdity of Warsaw, Warsaw, Mazowieckie, Poland
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Journal of Cardiovascular Computed Tomography
Verified
Journal Article
Closed access
Maksymilian OpolskiMaksymilian Opolski
Maksymilian Opolski
ADArtur Debski
Artur Debski
BBBartosz A. Borucki
Bartosz A. Borucki
ASAdam D. Staruch
Adam D. Staruch
CKCezary Kepka
Cezary Kepka
AWAdam Witkowski
Adam Witkowski

22 September 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JRJoanna Katarzyna Rogozik
Joanna Katarzyna Rogozik
Jakub Kosma RokickiJakub Kosma Rokicki
Jakub Kosma Rokicki
MGMarcin Grabowski
Marcin Grabowski
RGRenata Główczyńska
Renata Główczyńska
Background: Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder characterized by significantly elevated levels of low-density lipoprotein (LDL) cholesterol, which plays a major role in the progression of atherosclerosis and leads to a heightened risk of premature atherosclerotic cardiovascular disease. Methods: We have carried out an observational study on a group of 17 patients treated at the Outpatient Lipid Clinic from 2019 to 2024. Result: The most frequent mutation observed was found in the LDL receptor (LDLR) gene, which was identified in ten patients (58.8%). Five patients were identified to have a mutation in the apolipoprotein B (APOB) gene, whereas two patients had two points mutations, one in the LDLR, and the other in the APOB gene. The average age of patients with LDLR mutation was 54.8 (12.3); for APOB mutation it was 61.4 (9.3) and for patients with two points mutation it was 61.5 (14.8). The study results showed that at Week 12, individuals with LDLR-defective heterozygotes who were given alirocumab 150 mg every two weeks experienced a 63.0% reduction in LDL cholesterol levels. On the other hand, individuals with APOB heterozygotes experienced a 59% reduction in LDL cholesterol levels. However, in patients with double heterozygous for mutations in LDLR and APOB genes, there was a hyporesponsiveness to alirocumab, and the reduction in LDL-C was only by 23% in two individuals. Conclusions: In patients with a single mutation, there was a greater response to treatment with alirocumab in contrast to patients with double heterozygous mutation, who did not respond to treatment with PCSK9 inhibitors.

Verified
Journal Article
Open access
PDF file
BKBartosz Krzowski
Bartosz Krzowski
Jakub Kosma RokickiJakub Kosma Rokicki
Jakub Kosma Rokicki
RGRenata Główczyńska
Renata Główczyńska
NFNikola Fajkis-Zajączkowska
Nikola Fajkis-Zajączkowska
KBKatarzyna Barczewska
Katarzyna Barczewska
PBPaweł Balsam
Paweł Balsam
Background: Cardiovascular disease remains the leading cause of death in the European Union and worldwide. Constant improvement in cardiac care is leading to an increased number of patients with heart failure, which is a challenging condition in terms of clinical management. Cardiac resynchronization therapy is becoming more popular because of its grounded position in guidelines and clinical practice. However, some patients do not respond to treatment as expected. One way of assessing cardiac resynchronization therapy is with ECG analysis. Artificial intelligence is increasing in terms of everyday usability due to the possibility of everyday workflow improvement and, as a result, shortens the time required for diagnosis. A special area of artificial intelligence is machine learning. AI algorithms learn on their own based on implemented data. The aim of this study was to evaluate using artificial intelligence algorithms for detecting inadequate resynchronization therapy. Methods: A total of 1241 ECG tracings were collected from 547 cardiac department patients. All ECG signals were analyzed by three independent cardiologists. Every signal event (QRS-complex) and rhythm was manually classified by the medical team and fully reviewed by additional cardiologists. The results were divided into two parts: 80% of the results were used to train the algorithm, and 20% were used for the test (Cardiomatics, Cracow, Poland). Results: The required level of detection sensitivity of effective cardiac resynchronization therapy stimulation was achieved: 99.2% with a precision of 92.4%. Conclusions: Artificial intelligence algorithms can be a useful tool in assessing the effectiveness of resynchronization therapy.

10 January 2022 in European Heart Journal
Verified
Journal Article
Closed access
PDF file
MMMarcin Michalak
Marcin Michalak
Jakub Kosma RokickiJakub Kosma Rokicki
Jakub Kosma Rokicki
ARAdam Rdzanek
Adam Rdzanek
MGMarcin Grabowski
Marcin Grabowski
Transcatheter tricuspid valve interventions (TTVI) are newly emerged treatments for patients with severe tricuspid valve regurgitation. The most common TTVI technique is the edge-to-edge plication of tricuspid valve leaflets with MitraClip XTR device (Abbott, USA). Significant percentage of patients undergoing TTVI may have or require implantation of ventricular lead as part of pacing or implantable cardioverter-defibrillator (ICD) system in the future. The concomitant presence of both devices may pose a threat to inter-device interactions and significantly decrease lead durability. We present a case of 72-year-old male with early defibrillation lead failure referred for transvenous lead extraction (TLE). The single-chamber ICD with single-coil defibrillation lead (Plexa S 65, Biotronik, Germany) was implanted in November 2019 in primary prevention. One month later, the patient underwent MitraClip XTR implantation in mitral and tricuspid position due to severe symptomatic regurgitation (Panel A and see Supplementary material online, Video S1) with good echocardiographic and clinical effect. In September 2021, he received recurrent shocks from the ICD caused by short R–R intervals counted in VF zone (Panel B). The patient was qualified for TLE procedure. The lead was removed easily with simple traction. Due to high percentage of ventricular pacing, cardiac resynchronization therapy with defibrillator was implanted. Later, visual examination of the lead revealed severe insulation defect with conductor externalization (Panel C) at the site adjacent to tricuspid valve. To the best of our knowledge, this is the first case described, where lead failure was caused by collision with MitraClip device.

19 April 2023 in Advances in Clinical and Experimental Medicine
Verified
Journal Article
Open access
APAndrzej Przybylski
Andrzej Przybylski
DJDariusz Jagielski
Dariusz Jagielski
BHBruno Hrymniak
Bruno Hrymniak
MMMarcin Michalak
Marcin Michalak
TWTomasz Wójcik
Tomasz Wójcik
MSMaciej Sterliński
Maciej Sterliński
Background. Transvenous lead extraction (TLE) is recommended in cases of local and systemic infections related to cardiac implantable electronic devices (CIEDs). Additionally, TLE is indicated in the event of lead damage or CIED malfunction. The extraction procedure is associated with a risk of life-threatening complications. Objectives. The aim of the EVO registry was to assess the safety and efficacy of birotational Evolution tool usage. Materials and methods. This registry study was prospectively conducted in 8 high-volume implantation centers in Poland. The study included 133 patients aged 63.5 +/- 15.1 years, and 76.69% were male. Indications for the procedure were: local or systemic infection (33.1%) and lead dysfunction (66.9%). The number of leads extracted varied from 1 (39.84%) to 3 (9.77%). Results. Clinical procedural success was achieved in 99.1% of cases. A total of 226 leads were extracted, and 206 used the Evolution system. Two procedural strategies were identified while using the Evolution system: (1) usage of locking stylet, propylene sheaths and the Evolution system (118 leads, 52%) - group A; (2) usage of locking styletand Evolution (88 leads, 39%) - group B. There were no differences in the number of complications between these 2 groups. The extraction time was significantly shorter (p = 0.02) in group B than in group A. Major complications occurred in 5.2% of cases with 2 intraprocedural deaths. Minor complications occurred in 1.5% of patients. Conclusions. The registry confirmed the efficacy and relative safety of the birotational Evolution sheath. Using the rotational sheath as a first attempt significantly reduces extraction time without compromising its safety.

2 September 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MBMaria Boszko
Maria Boszko
BKBartosz Krzowski
Bartosz Krzowski
MGMichał Gawlik
Michał Gawlik
ASAlicja Skrobucha
Alicja Skrobucha
JSJulia Szydlik
Julia Szydlik
PBPaweł Balsam
Paweł Balsam
Background/Objectives: Hepatic steatosis and metabolic dysfunction-associated steatotic liver disease (MASLD) are cardiometabolic phenotypes relevant to atrial fibrillation (AF), but their prevalence and acute procedural relevance in pulsed field ablation (PFA) are poorly defined. We estimated the prevalence of hepato-renal index (HRI)-detected hepatic steatosis, assessed liver marker concordance, and explored acute procedural characteristics. Methods: In this single-centre prospective study, 99 consecutive eligible patients undergoing first-time PFA for AF underwent B-mode hepatic ultrasound. Hepatic steatosis was defined a priori as HRI ≥ 1.28, measured offline by an investigator blinded to clinical and procedural data. HRI-based MASLD-compatible phenotype, Hepatic Steatosis Index (HSI), BARD score, and Fibrosis-4 index were analysed as secondary liver markers. Results: HRI-detected hepatic steatosis was present in 62/99 patients (62.6%, 95% CI 52.8–71.5), and HRI-based MASLD-compatible phenotype in 55/99 (55.6%, 95% CI 45.7–65.0). Agreement between HRI and HSI was poor (Cohen’s κ = 0.01; prevalence-adjusted bias-adjusted κ +0.06; positive agreement 62%). Acute pulmonary vein isolation was achieved in all patients. First-pass isolation was high in both groups (91.9% vs. 81.1%; p = 0.124). Most procedural metrics were similar. Fluoroscopy dose was modestly higher in patients with steatosis (median 226 vs. 207 mGy; p = 0.035), but this exploratory signal was inconsistent across sensitivity analyses. In-hospital complications were infrequent (4/99, 4.0%). Conclusions: In first-time PFA patients with feasible HRI assessment, hepatic steatosis was common, liver marker classifications showed limited patient-level agreement, and acute procedural conduct showed no consistent steatosis-specific signal. Long-term rhythm durability requires dedicated follow-up.